Skip to content
Screener

Roivant Sciences ROIV United States — Federal research tax credit carryforwards

Similar metrics at other companies

Liberty Latin America logo
LILAUnited States — Tax credit carryforwards
$21M+110%
Novanta logo
NOVTUS Federal Foreign Tax Credits — Tax Credit Carryforward Amount
$500K0.0%
Belden logo
BDCUnited  States — Net tax credit carryforwards that will expire
$9.12M-30.1%
Novanta logo
NOVTUS State Credits — Tax Credit Carryforward Amount
$2.7M+3.8%
Lifecore Biomedical, Inc. logo
LFCRAll other states — Tax credit carryforward amount
$2.02M
California Resources logo
CRCCALIFORNIA — Tax credit carryforward
$21M0.0%

Other financials

Income statement

See full
Revenue$1.4M-33.5%
Operating income-$366.0M-28.5%
Net income-$189.8M+15.0%
EPS (diluted)-$0.26+21.2%

Balance sheet

See full
Cash & equivalents$77.1M-18.7%
Total debt$107.2M+7.5%
Total equity$4.2B-2.6%
Total assets$5.3B+5.4%

Cash flow

See full
Operating cash flow-$270.5M-32.4%
CapEx$419.0K-89.6%
Free cash flow-$270.9M-30.0%

Valuation

See full
Market cap$25.37B+219%
Enterprise value$25.4B+219%
P/S3,368×+3,026×

Profitability

See full
Operating margin-9,130.5%-13,995pp
Net margin-6,079.9%-6,193pp
FCF margin-10,901%-22,382pp

Returns & leverage

See full
Return on equity-17.1%-17.7pp
Debt / equity0.0×
Current ratio16.7×-23.8×

Where this comes from

Reported directly by Roivant Sciences in its filing.

Tagged under the XBRL concept us-gaap:TaxCreditCarryforwardAmount.

The source filing: Roivant Sciences’s 10-K, filed May 20, 2026.

Filed
May 20, 2026, 7:17 AM EDT
Fiscal year
FY2025
Accession
0001635088-26-000061

The Company has net operating losses in Switzerland, the U.S. and the U.K. in the amount of $1,512.9 million, $890.7 million and $613.4 million, respectively. The Switzerland net operating losses will expire in varying amounts between March 31, 2027 and March 31, 2032. The U.S. net operating losses can be carried forward indefinitely with utilization limited to 80% of future taxable income for tax years beginning on or after January 1, 2021, while the U.K. and other net operating losses can be carried forward indefinitely as well, with an annual limitation on utilization. The Company has $66.0 million of federal research tax credit carryforwards in the U.S., which will expire in varying amounts between March 31, 2039 and March 31, 2046. Additionally, credits of $10.8 million are related to various states and Canada.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

FAQ

What is Roivant Sciences's united states — federal research tax credit carryforwards?
Roivant Sciences (ROIV) reported united states — federal research tax credit carryforwards of $66M in Q1 2026.
What does united states — federal research tax credit carryforwards mean?
This represents the accumulated federal research and development tax credits that have not yet been utilized to offset U.S. tax liabilities. These credits are generated by the company's investment in innovation and drug development activities. They represent a valuable asset that can be applied to reduce future federal income tax obligations.

Ask your AI about Roivant Sciences's united states — federal research tax credit carryforwards.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude